Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates
Open Access
- 27 September 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-9
Abstract
The ongoing evolution of the SARS-CoV-2 virus has led to a move to update vaccine antigens in 2022 and 2023. These updated antigens were chosen and approved based largely on in vitro neutralisation titres against recent SARS-CoV-2 variants. However, unavoidable delays in vaccine manufacture and distribution meant that the updated booster vaccine was no longer well-matched to the circulating SARS-CoV-2 variant by the time of its deployment. Understanding whether the updating of booster vaccine antigens improves immune responses to subsequent SARS-CoV-2 circulating variants is a major priority in justifying future vaccine updates. Here we analyse all available data on the immunogenicity of variants containing SARS-CoV-2 vaccines and their ability to neutralise later circulating SARS-CoV-2 variants. We find that updated booster antigens give a 1.4-fold [95% CI: 1.07–1.82] greater increase in neutralising antibody levels when compared with a historical vaccine immunogen. We then use this to predict the relative protection that can be expected from an updated vaccine even when the circulating variant has evolved away from the updated vaccine immunogen. These findings help inform the rollout of future booster vaccination programmes.Keywords
All Related Versions
Funding Information
- Department of Health | National Health and Medical Research Council (1173528)
This publication has 46 references indexed in Scilit:
- A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domainNature Communications, 2022
- Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trialNature Medicine, 2022
- A Bivalent Omicron-Containing Booster Vaccine against Covid-19New England Journal of Medicine, 2022
- Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of OmicronImmunity, 2022
- Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster VaccineNew England Journal of Medicine, 2022
- Influenza virus infection history shapes antibody responses to influenza vaccinationNature Medicine, 2022
- SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster VaccinationNew England Journal of Medicine, 2022
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Measuring immunity to SARS-CoV-2 infection: comparing assays and animal modelsNature Reviews Immunology, 2020
- Variable efficacy of repeated annual influenza vaccinationProceedings of the National Academy of Sciences, 1999